Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors.
Takagi M, Ogawa C, Iehara T, Aoki-Nogami Y, Ishibashi E, Imai M, Kimura T, Nagata M, Yasuhara M, Masutani M, Yoshimura K, Tomizawa D, Ogawa A, Yonemori K, Morishita A, Miyamoto S, Takita J, Kihara T, Nobori K, Hasebe K, Miya F, Ikeda S, Shioda Y, Matsumoto K, Fujimura J, Mizutani S, Morio T, Hosoi H, Koike R. Takagi M, et al. Among authors: ishibashi e. Cancer. 2022 Aug 1;128(15):2949-2957. doi: 10.1002/cncr.34270. Epub 2022 May 20. Cancer. 2022. PMID: 35593736 Free article. Clinical Trial.
[Clinical Utility of Comprehensive Genome Profiling Using FoundationOne CDx in Japanese Population(PROFILE-F Study)].
Kumaki Y, Takahashi K, Mitsumura T, Yokobori J, Takamine E, Ishibashi E, Sakashita H, Ishikawa T, Ono H, Ban D, Kudo A, Oshima N, Nakagawa T, Kimura K, Kubota K, Onishi I, Tanabe M, Uetake H, Miyake S, Ikeda S. Kumaki Y, et al. Among authors: ishibashi e. Gan To Kagaku Ryoho. 2019 Nov;46(11):1715-1719. Gan To Kagaku Ryoho. 2019. PMID: 31748480 Japanese.
A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial).
Takahashi K, Ishibashi E, Kubo T, Harada Y, Hayashi H, Kano M, Shimizu Y, Shirota H, Mori Y, Muto M, Ishioka C, Dosaka-Akita H, Matsubara H, Nishihara H, Sueoka-Aragane N, Toyooka S, Hirakawa A, Tateishi U, Miyake S, Ikeda S. Takahashi K, et al. Among authors: ishibashi e. Medicine (Baltimore). 2020 Aug 7;99(32):e21457. doi: 10.1097/MD.0000000000021457. Medicine (Baltimore). 2020. PMID: 32769873 Free PMC article.
Efficacy of ezetimibe for reducing serum low-density lipoprotein cholesterol levels resistant to lifestyle intervention in patients with non-alcoholic fatty liver disease.
Oza N, Takahashi H, Eguchi Y, Kitajima Y, Kuwashiro T, Ishibashi E, Nakashita S, Iwane S, Kawaguchi Y, Mizuta T, Ozaki I, Ono N, Eguchi T, Fujimoto K, Anzai K. Oza N, et al. Among authors: ishibashi e. Hepatol Res. 2014 Jul;44(7):812-7. doi: 10.1111/hepr.12176. Epub 2013 Jun 25. Hepatol Res. 2014. PMID: 23721476
The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease.
Eguchi Y, Mizuta T, Sumida Y, Ishibashi E, Kitajima Y, Isoda H, Horie H, Tashiro T, Iwamoto E, Takahashi H, Kuwashiro T, Soejima S, Kawaguchi Y, Oda Y, Emura S, Iwakiri R, Ozaki I, Eguchi T, Ono N, Anzai K, Fujimoto K, Koizumi S. Eguchi Y, et al. Among authors: ishibashi e. J Gastroenterol. 2011 Jan;46 Suppl 1:70-8. doi: 10.1007/s00535-010-0340-3. Epub 2010 Nov 2. J Gastroenterol. 2011. PMID: 21042922
19 results